#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2. Obesity Before Liver Transplantation
1-1	0-2	2.	_	_	_	_
1-2	3-10	Obesity	abstract[1]	new[1]	coref	2-4[0_1]
1-3	11-17	Before	abstract[1]	new[1]	_	_
1-4	18-23	Liver	abstract[1]|object|abstract[3]	new[1]|new|new[3]	coref	11-7
1-5	24-39	Transplantation	abstract[1]|abstract[3]	new[1]|new[3]	_	_

#Text=2.1. How Should Obesity be Defined in Patients with Cirrhosis Considered for LT ?
2-1	40-44	2.1.	_	_	_	_
2-2	45-48	How	_	_	_	_
2-3	49-55	Should	_	_	_	_
2-4	56-63	Obesity	abstract	giv	coref	3-7
2-5	64-66	be	_	_	_	_
2-6	67-74	Defined	_	_	_	_
2-7	75-77	in	_	_	_	_
2-8	78-86	Patients	person[5]	new[5]	coref	4-15[0_5]
2-9	87-91	with	person[5]	new[5]	_	_
2-10	92-101	Cirrhosis	person[5]|substance[6]	new[5]|new[6]	coref	6-11[45_6]
2-11	102-112	Considered	person[5]|substance[6]	new[5]|new[6]	_	_
2-12	113-116	for	person[5]|substance[6]	new[5]|new[6]	_	_
2-13	117-119	LT	person[5]|substance[6]|abstract	new[5]|new[6]|new	coref	6-29
2-14	120-121	?	_	_	_	_

#Text=The first obstacle is to define obesity in this population .
3-1	122-125	The	abstract[8]	new[8]	_	_
3-2	126-131	first	abstract[8]	new[8]	_	_
3-3	132-140	obstacle	abstract[8]	new[8]	_	_
3-4	141-143	is	_	_	_	_
3-5	144-146	to	_	_	_	_
3-6	147-153	define	_	_	_	_
3-7	154-161	obesity	abstract	giv	coref	7-17[55_0]
3-8	162-164	in	_	_	_	_
3-9	165-169	this	person[10]	new[10]	coref	5-7[17_10]
3-10	170-180	population	person[10]	new[10]	_	_
3-11	181-182	.	_	_	_	_

#Text=Elamparast et al. recently summarized the most commonly used definitions in this group of patients :
4-1	183-193	Elamparast	person	new	_	_
4-2	194-196	et	_	_	_	_
4-3	197-200	al.	_	_	_	_
4-4	201-209	recently	_	_	_	_
4-5	210-220	summarized	_	_	_	_
4-6	221-224	the	abstract[12]	new[12]	_	_
4-7	225-229	most	abstract[12]	new[12]	_	_
4-8	230-238	commonly	abstract[12]	new[12]	_	_
4-9	239-243	used	abstract[12]	new[12]	_	_
4-10	244-255	definitions	abstract[12]	new[12]	_	_
4-11	256-258	in	_	_	_	_
4-12	259-263	this	animal[13]	new[13]	_	_
4-13	264-269	group	animal[13]	new[13]	_	_
4-14	270-272	of	animal[13]	new[13]	_	_
4-15	273-281	patients	animal[13]|person	new[13]|giv	coref	6-9[44_0]
4-16	282-283	:	_	_	_	_

#Text=- BMI ≥ 30 kg/m2 ( Asian population : ≥25 kg/m2 ) ; - Percentage of fat mass ≥28 % in men and ≥40 % in women ; - Waist circumference ˃102 cm in men and ˃88 cm in women ( Asian population : A waist circumference ˃90 cm in men and ˃80 cm in women ) ; - Visceral fat area ≥100 cm2 on abdominal computed tomography .
5-1	284-285	-	_	_	_	_
5-2	286-289	BMI	organization	new	coref	6-4
5-3	290-291	≥	_	_	_	_
5-4	292-294	30	abstract[16]	new[16]	appos	5-10[18_16]
5-5	295-300	kg/m2	abstract[16]	new[16]	_	_
5-6	301-302	(	_	_	_	_
5-7	303-308	Asian	person[17]	giv[17]	_	_
5-8	309-319	population	person[17]	giv[17]	_	_
5-9	320-321	:	_	_	_	_
5-10	322-325	≥25	abstract[18]	giv[18]	coref	15-11[0_18]
5-11	326-331	kg/m2	abstract[18]	giv[18]	_	_
5-12	332-333	)	_	_	_	_
5-13	334-335	;	_	_	_	_
5-14	336-337	-	_	_	_	_
5-15	338-348	Percentage	abstract[19]	new[19]	_	_
5-16	349-351	of	abstract[19]	new[19]	_	_
5-17	352-355	fat	abstract[19]|substance|abstract[21]	new[19]|new|new[21]	coref	5-61
5-18	356-360	mass	abstract[19]|abstract[21]	new[19]|new[21]	_	_
5-19	361-364	≥28	_	_	_	_
5-20	365-366	%	_	_	_	_
5-21	367-369	in	_	_	_	_
5-22	370-373	men	person	new	coref	5-35
5-23	374-377	and	_	_	_	_
5-24	378-381	≥40	_	_	_	_
5-25	382-383	%	_	_	_	_
5-26	384-386	in	_	_	_	_
5-27	387-392	women	person	new	coref	5-40
5-28	393-394	;	_	_	_	_
5-29	395-396	-	_	_	_	_
5-30	397-402	Waist	object|place[25]	new|new[25]	coref|coref	5-46|5-45[32_25]
5-31	403-416	circumference	place[25]	new[25]	_	_
5-32	417-421	˃102	time|abstract[27]	new|new[27]	coref	5-37[29_27]
5-33	422-424	cm	abstract[27]	new[27]	_	_
5-34	425-427	in	abstract[27]	new[27]	_	_
5-35	428-431	men	abstract[27]|person	new[27]|giv	coref	5-51
5-36	432-435	and	_	_	_	_
5-37	436-439	˃88	abstract[29]	giv[29]	coref	5-49[34_29]
5-38	440-442	cm	abstract[29]	giv[29]	_	_
5-39	443-445	in	_	_	_	_
5-40	446-451	women	person	giv	coref	5-56
5-41	452-453	(	_	_	_	_
5-42	454-459	Asian	_	_	_	_
5-43	460-470	population	_	_	_	_
5-44	471-472	:	_	_	_	_
5-45	473-474	A	place[32]	giv[32]	coref	13-6[113_32]
5-46	475-480	waist	object|place[32]	giv|giv[32]	coref	13-6
5-47	481-494	circumference	place[32]	giv[32]	_	_
5-48	495-498	˃90	time	new	_	_
5-49	499-501	cm	abstract[34]	giv[34]	coref	5-53[36_34]
5-50	502-504	in	abstract[34]	giv[34]	_	_
5-51	505-508	men	abstract[34]|person	giv[34]|giv	_	_
5-52	509-512	and	_	_	_	_
5-53	513-516	˃80	abstract[36]	giv[36]	_	_
5-54	517-519	cm	abstract[36]	giv[36]	_	_
5-55	520-522	in	_	_	_	_
5-56	523-528	women	person	giv	_	_
5-57	529-530	)	_	_	_	_
5-58	531-532	;	_	_	_	_
5-59	533-534	-	_	_	_	_
5-60	535-543	Visceral	abstract[39]	new[39]	coref	16-14[152_39]
5-61	544-547	fat	substance|abstract[39]	giv|new[39]	coref	10-1[89_0]
5-62	548-552	area	abstract[39]	new[39]	_	_
5-63	553-557	≥100	abstract[39]	new[39]	_	_
5-64	558-561	cm2	abstract[39]	new[39]	_	_
5-65	562-564	on	abstract[39]	new[39]	_	_
5-66	565-574	abdominal	abstract[39]|object[40]	new[39]|new[40]	_	_
5-67	575-583	computed	abstract[39]|object[40]	new[39]|new[40]	_	_
5-68	584-594	tomography	abstract[39]|object[40]	new[39]|new[40]	_	_
5-69	595-596	.	_	_	_	_

#Text=The use of BMI has several limitations in patients with decompensated cirrhosis , as reflected by the fact that sarcopenia outperforms BMI as a predictor of outcomes after LT .
6-1	597-600	The	event[41]	new[41]	coref	15-30[148_41]
6-2	601-604	use	event[41]	new[41]	_	_
6-3	605-607	of	event[41]	new[41]	_	_
6-4	608-611	BMI	event[41]|organization	new[41]|giv	coref	6-22
6-5	612-615	has	_	_	_	_
6-6	616-623	several	abstract[43]	new[43]	coref	14-6[118_43]
6-7	624-635	limitations	abstract[43]	new[43]	_	_
6-8	636-638	in	_	_	_	_
6-9	639-647	patients	person[44]	giv[44]	coref	7-46[0_44]
6-10	648-652	with	person[44]	giv[44]	_	_
6-11	653-666	decompensated	person[44]|substance[45]	giv[44]|giv[45]	coref	9-33[0_45]
6-12	667-676	cirrhosis	person[44]|substance[45]	giv[44]|giv[45]	_	_
6-13	677-678	,	_	_	_	_
6-14	679-681	as	_	_	_	_
6-15	682-691	reflected	_	_	_	_
6-16	692-694	by	_	_	_	_
6-17	695-698	the	abstract[46]	new[46]	coref	12-3[105_46]
6-18	699-703	fact	abstract[46]	new[46]	_	_
6-19	704-708	that	abstract[46]	new[46]	_	_
6-20	709-719	sarcopenia	abstract[46]|abstract	new[46]|new	coref	9-12
6-21	720-731	outperforms	abstract[46]	new[46]	_	_
6-22	732-735	BMI	abstract[46]|organization	new[46]|giv	coref	7-5[52_0]
6-23	736-738	as	abstract[46]	new[46]	_	_
6-24	739-740	a	abstract[46]|abstract[49]	new[46]|new[49]	_	_
6-25	741-750	predictor	abstract[46]|abstract[49]	new[46]|new[49]	_	_
6-26	751-753	of	abstract[46]|abstract[49]	new[46]|new[49]	_	_
6-27	754-762	outcomes	abstract[46]|abstract[49]|abstract[50]	new[46]|new[49]|new[50]	coref	14-71[137_50]
6-28	763-768	after	abstract[46]|abstract[49]|abstract[50]	new[46]|new[49]|new[50]	_	_
6-29	769-771	LT	abstract[46]|abstract[49]|abstract[50]|abstract	new[46]|new[49]|new[50]|giv	coref	7-40
6-30	772-773	.	_	_	_	_

#Text=First of all , a high BMI may be due to fluid overload/ascites , and not obesity per se , as exemplified in a study in which adjusting BMI for the liters of ascites drained at the time of LT resulted in moving one-fifth of patients from one BMI category to a lower one .
7-1	774-779	First	_	_	_	_
7-2	780-782	of	_	_	_	_
7-3	783-786	all	_	_	_	_
7-4	787-788	,	_	_	_	_
7-5	789-790	a	organization[52]	giv[52]	coref	7-29[0_52]
7-6	791-795	high	organization[52]	giv[52]	_	_
7-7	796-799	BMI	organization[52]	giv[52]	_	_
7-8	800-803	may	_	_	_	_
7-9	804-806	be	_	_	_	_
7-10	807-810	due	_	_	_	_
7-11	811-813	to	_	_	_	_
7-12	814-819	fluid	substance|event[54]	new|new[54]	coref	14-35
7-13	820-836	overload/ascites	event[54]	new[54]	_	_
7-14	837-838	,	_	_	_	_
7-15	839-842	and	_	_	_	_
7-16	843-846	not	_	_	_	_
7-17	847-854	obesity	abstract[55]	giv[55]	coref	10-13[92_55]
7-18	855-858	per	abstract[55]	giv[55]	_	_
7-19	859-861	se	abstract[55]|abstract	giv[55]|new	ana	8-11
7-20	862-863	,	_	_	_	_
7-21	864-866	as	_	_	_	_
7-22	867-878	exemplified	_	_	_	_
7-23	879-881	in	_	_	_	_
7-24	882-883	a	abstract[57]	new[57]	coref	14-13[120_57]
7-25	884-889	study	abstract[57]	new[57]	_	_
7-26	890-892	in	abstract[57]	new[57]	_	_
7-27	893-898	which	abstract[57]	new[57]	_	_
7-28	899-908	adjusting	abstract[57]	new[57]	_	_
7-29	909-912	BMI	abstract[57]|organization	new[57]|giv	coref	7-49
7-30	913-916	for	abstract[57]	new[57]	_	_
7-31	917-920	the	abstract[57]|substance[59]	new[57]|new[59]	_	_
7-32	921-927	liters	abstract[57]|substance[59]	new[57]|new[59]	_	_
7-33	928-930	of	abstract[57]|substance[59]	new[57]|new[59]	_	_
7-34	931-938	ascites	abstract[57]|substance[59]|abstract	new[57]|new[59]|new	coref	14-52
7-35	939-946	drained	abstract[57]|substance[59]	new[57]|new[59]	_	_
7-36	947-949	at	abstract[57]|substance[59]	new[57]|new[59]	_	_
7-37	950-953	the	abstract[57]|substance[59]	new[57]|new[59]	_	_
7-38	954-958	time	abstract[57]|substance[59]	new[57]|new[59]	_	_
7-39	959-961	of	abstract[57]|substance[59]	new[57]|new[59]	_	_
7-40	962-964	LT	abstract[57]|substance[59]|abstract	new[57]|new[59]|giv	coref	14-67
7-41	965-973	resulted	abstract[57]	new[57]	_	_
7-42	974-976	in	_	_	_	_
7-43	977-983	moving	_	_	_	_
7-44	984-993	one-fifth	object[62]	new[62]	_	_
7-45	994-996	of	object[62]	new[62]	_	_
7-46	997-1005	patients	object[62]|person	new[62]|giv	coref	9-28[87_0]
7-47	1006-1010	from	_	_	_	_
7-48	1011-1014	one	abstract[65]	new[65]	_	_
7-49	1015-1018	BMI	organization|abstract[65]	giv|new[65]	coref	8-3
7-50	1019-1027	category	abstract[65]	new[65]	_	_
7-51	1028-1030	to	_	_	_	_
7-52	1031-1032	a	object[66]	new[66]	coref	9-14[84_66]
7-53	1033-1038	lower	object[66]	new[66]	_	_
7-54	1039-1042	one	object[66]	new[66]	_	_
7-55	1043-1044	.	_	_	_	_

#Text=Also , BMI gives no information about body composition : It cannot tell the difference between muscle , subcutaneous , or visceral adipose tissue , which have different implications .
8-1	1045-1049	Also	_	_	_	_
8-2	1050-1051	,	_	_	_	_
8-3	1052-1055	BMI	organization	giv	coref	9-21
8-4	1056-1061	gives	_	_	_	_
8-5	1062-1064	no	abstract[68]	new[68]	_	_
8-6	1065-1076	information	abstract[68]	new[68]	_	_
8-7	1077-1082	about	abstract[68]	new[68]	_	_
8-8	1083-1087	body	abstract[68]|object|abstract[70]	new[68]|new|new[70]	coref|coref	9-4|9-4[79_70]
8-9	1088-1099	composition	abstract[68]|abstract[70]	new[68]|new[70]	_	_
8-10	1100-1101	:	_	_	_	_
8-11	1102-1104	It	abstract	giv	_	_
8-12	1105-1111	cannot	_	_	_	_
8-13	1112-1116	tell	_	_	_	_
8-14	1117-1120	the	abstract[72]	new[72]	_	_
8-15	1121-1131	difference	abstract[72]	new[72]	_	_
8-16	1132-1139	between	abstract[72]	new[72]	_	_
8-17	1140-1146	muscle	abstract[72]|object	new[72]|new	_	_
8-18	1147-1148	,	abstract[72]	new[72]	_	_
8-19	1149-1161	subcutaneous	abstract[72]	new[72]	_	_
8-20	1162-1163	,	abstract[72]	new[72]	_	_
8-21	1164-1166	or	abstract[72]	new[72]	_	_
8-22	1167-1175	visceral	abstract[72]|object[75]	new[72]|new[75]	_	_
8-23	1176-1183	adipose	abstract[72]|abstract|object[75]	new[72]|new|new[75]	coref	9-16
8-24	1184-1190	tissue	abstract[72]|object[75]	new[72]|new[75]	_	_
8-25	1191-1192	,	abstract[72]|object[75]	new[72]|new[75]	_	_
8-26	1193-1198	which	abstract[72]|object[75]	new[72]|new[75]	_	_
8-27	1199-1203	have	abstract[72]|object[75]	new[72]|new[75]	_	_
8-28	1204-1213	different	abstract[72]|object[75]|abstract[76]	new[72]|new[75]|new[76]	_	_
8-29	1214-1226	implications	abstract[72]|object[75]|abstract[76]	new[72]|new[75]|new[76]	_	_
8-30	1227-1228	.	_	_	_	_

#Text=Studies looking at body composition on cross-sectional imaging have found that sarcopenia and low subcutaneous adipose tissue , but not BMI , are associated with mortality in male and female patients with cirrhosis , respectively .
9-1	1229-1236	Studies	event[77]	new[77]	_	_
9-2	1237-1244	looking	event[77]	new[77]	_	_
9-3	1245-1247	at	event[77]	new[77]	_	_
9-4	1248-1252	body	event[77]|object|abstract[79]	new[77]|giv|giv[79]	coref|coref	12-22[110_79]|16-19
9-5	1253-1264	composition	event[77]|abstract[79]	new[77]|giv[79]	_	_
9-6	1265-1267	on	event[77]	new[77]	_	_
9-7	1268-1283	cross-sectional	event[77]|abstract[80]	new[77]|new[80]	_	_
9-8	1284-1291	imaging	event[77]|abstract[80]	new[77]|new[80]	_	_
9-9	1292-1296	have	_	_	_	_
9-10	1297-1302	found	_	_	_	_
9-11	1303-1307	that	_	_	_	_
9-12	1308-1318	sarcopenia	abstract|abstract[82]	giv|new[82]	coref|coref	10-7|16-43[163_82]
9-13	1319-1322	and	abstract[82]	new[82]	_	_
9-14	1323-1326	low	abstract[82]|object[84]	new[82]|giv[84]	coref	11-25[101_84]
9-15	1327-1339	subcutaneous	abstract[82]|object[84]	new[82]|giv[84]	_	_
9-16	1340-1347	adipose	abstract[82]|abstract|object[84]	new[82]|giv|giv[84]	coref	16-50
9-17	1348-1354	tissue	abstract[82]|object[84]	new[82]|giv[84]	_	_
9-18	1355-1356	,	abstract[82]	new[82]	_	_
9-19	1357-1360	but	abstract[82]	new[82]	_	_
9-20	1361-1364	not	abstract[82]	new[82]	_	_
9-21	1365-1368	BMI	abstract[82]|organization	new[82]|giv	coref	12-17[108_0]
9-22	1369-1370	,	_	_	_	_
9-23	1371-1374	are	_	_	_	_
9-24	1375-1385	associated	_	_	_	_
9-25	1386-1390	with	_	_	_	_
9-26	1391-1400	mortality	event[86]	new[86]	coref	10-20[93_86]
9-27	1401-1403	in	event[86]	new[86]	_	_
9-28	1404-1408	male	event[86]|person[87]	new[86]|giv[87]	coref	11-5[97_87]
9-29	1409-1412	and	event[86]|person[87]	new[86]|giv[87]	_	_
9-30	1413-1419	female	event[86]|person[87]	new[86]|giv[87]	_	_
9-31	1420-1428	patients	event[86]|person[87]	new[86]|giv[87]	_	_
9-32	1429-1433	with	event[86]|person[87]	new[86]|giv[87]	_	_
9-33	1434-1443	cirrhosis	event[86]|person[87]|substance	new[86]|giv[87]|giv	coref	14-24
9-34	1444-1445	,	_	_	_	_
9-35	1446-1458	respectively	_	_	_	_
9-36	1459-1460	.	_	_	_	_

#Text=Excessive visceral fat when associated with sarcopenia , a term known as sarcopenic obesity , is also associated with increased mortality .
10-1	1461-1470	Excessive	substance[89]	giv[89]	_	_
10-2	1471-1479	visceral	substance[89]	giv[89]	_	_
10-3	1480-1483	fat	substance[89]	giv[89]	_	_
10-4	1484-1488	when	substance[89]	giv[89]	_	_
10-5	1489-1499	associated	substance[89]	giv[89]	_	_
10-6	1500-1504	with	substance[89]	giv[89]	_	_
10-7	1505-1515	sarcopenia	substance[89]|abstract	giv[89]|giv	appos	10-9[91_0]
10-8	1516-1517	,	_	_	_	_
10-9	1518-1519	a	abstract[91]	giv[91]	coref	11-14[0_91]
10-10	1520-1524	term	abstract[91]	giv[91]	_	_
10-11	1525-1530	known	abstract[91]	giv[91]	_	_
10-12	1531-1533	as	abstract[91]	giv[91]	_	_
10-13	1534-1544	sarcopenic	abstract[91]|abstract[92]	giv[91]|giv[92]	coref	13-15[0_92]
10-14	1545-1552	obesity	abstract[91]|abstract[92]	giv[91]|giv[92]	_	_
10-15	1553-1554	,	_	_	_	_
10-16	1555-1557	is	_	_	_	_
10-17	1558-1562	also	_	_	_	_
10-18	1563-1573	associated	_	_	_	_
10-19	1574-1578	with	_	_	_	_
10-20	1579-1588	increased	event[93]	giv[93]	coref	11-37[0_93]
10-21	1589-1598	mortality	event[93]	giv[93]	_	_
10-22	1599-1600	.	_	_	_	_

#Text=In the case of living donor liver transplant ( LDLT ) patients , sarcopenia , myosteatosis , and the visceral-to-subcutaneous-adipose-tissue ratio , but not visceral or subcutaneous tissue on their own , have been associated with mortality .
11-1	1601-1603	In	_	_	_	_
11-2	1604-1607	the	abstract[94]	new[94]	_	_
11-3	1608-1612	case	abstract[94]	new[94]	_	_
11-4	1613-1615	of	abstract[94]	new[94]	_	_
11-5	1616-1622	living	abstract[94]|person[97]	new[94]|giv[97]	ana	11-30[0_97]
11-6	1623-1628	donor	abstract[94]|person[97]	new[94]|giv[97]	_	_
11-7	1629-1634	liver	abstract[94]|object|person[97]	new[94]|giv|giv[97]	coref	14-17
11-8	1635-1645	transplant	abstract[94]|person[97]	new[94]|giv[97]	_	_
11-9	1646-1647	(	abstract[94]|person[97]	new[94]|giv[97]	_	_
11-10	1648-1652	LDLT	abstract[94]|abstract|person[97]	new[94]|new|giv[97]	_	_
11-11	1653-1654	)	abstract[94]|person[97]	new[94]|giv[97]	_	_
11-12	1655-1663	patients	abstract[94]|person[97]	new[94]|giv[97]	_	_
11-13	1664-1665	,	_	_	_	_
11-14	1666-1676	sarcopenia	abstract	giv	coref	16-43
11-15	1677-1678	,	_	_	_	_
11-16	1679-1691	myosteatosis	abstract	new	coref	16-45
11-17	1692-1693	,	_	_	_	_
11-18	1694-1697	and	_	_	_	_
11-19	1698-1701	the	abstract[100]	new[100]	ana	12-1[0_100]
11-20	1702-1741	visceral-to-subcutaneous-adipose-tissue	abstract[100]	new[100]	_	_
11-21	1742-1747	ratio	abstract[100]	new[100]	_	_
11-22	1748-1749	,	_	_	_	_
11-23	1750-1753	but	_	_	_	_
11-24	1754-1757	not	_	_	_	_
11-25	1758-1766	visceral	object[101]	giv[101]	coref	16-48[166_101]
11-26	1767-1769	or	object[101]	giv[101]	_	_
11-27	1770-1782	subcutaneous	object[101]	giv[101]	_	_
11-28	1783-1789	tissue	object[101]	giv[101]	_	_
11-29	1790-1792	on	object[101]	giv[101]	_	_
11-30	1793-1798	their	object[101]|person	giv[101]|giv	coref	13-17[116_0]
11-31	1799-1802	own	object[101]	giv[101]	_	_
11-32	1803-1804	,	_	_	_	_
11-33	1805-1809	have	_	_	_	_
11-34	1810-1814	been	_	_	_	_
11-35	1815-1825	associated	_	_	_	_
11-36	1826-1830	with	_	_	_	_
11-37	1831-1840	mortality	event	giv	_	_
11-38	1841-1842	.	_	_	_	_

#Text=This reinforces the fact that more than the size of a patient , which is what the BMI stands for , it is the composition that matters .
12-1	1843-1847	This	abstract	giv	ana	12-22
12-2	1848-1858	reinforces	_	_	_	_
12-3	1859-1862	the	abstract[105]	giv[105]	_	_
12-4	1863-1867	fact	abstract[105]	giv[105]	_	_
12-5	1868-1872	that	abstract[105]	giv[105]	_	_
12-6	1873-1877	more	abstract[105]	giv[105]	_	_
12-7	1878-1882	than	abstract[105]	giv[105]	_	_
12-8	1883-1886	the	abstract[105]|abstract[106]	giv[105]|new[106]	_	_
12-9	1887-1891	size	abstract[105]|abstract[106]	giv[105]|new[106]	_	_
12-10	1892-1894	of	abstract[105]|abstract[106]	giv[105]|new[106]	_	_
12-11	1895-1896	a	abstract[105]|abstract[106]|person[107]	giv[105]|new[106]|new[107]	coref	23-17[223_107]
12-12	1897-1904	patient	abstract[105]|abstract[106]|person[107]	giv[105]|new[106]|new[107]	_	_
12-13	1905-1906	,	abstract[105]|abstract[106]	giv[105]|new[106]	_	_
12-14	1907-1912	which	abstract[105]|abstract[106]	giv[105]|new[106]	_	_
12-15	1913-1915	is	abstract[105]|abstract[106]	giv[105]|new[106]	_	_
12-16	1916-1920	what	abstract[105]|abstract[106]	giv[105]|new[106]	_	_
12-17	1921-1924	the	abstract[105]|abstract[106]|organization[108]	giv[105]|new[106]|giv[108]	coref	14-28[126_108]
12-18	1925-1928	BMI	abstract[105]|abstract[106]|organization[108]	giv[105]|new[106]|giv[108]	_	_
12-19	1929-1935	stands	abstract[105]|abstract[106]	giv[105]|new[106]	_	_
12-20	1936-1939	for	abstract[105]|abstract[106]	giv[105]|new[106]	_	_
12-21	1940-1941	,	abstract[105]	giv[105]	_	_
12-22	1942-1944	it	abstract[105]|abstract|abstract[110]	giv[105]|giv|giv[110]	coref	16-19[154_110]
12-23	1945-1947	is	abstract[105]|abstract[110]	giv[105]|giv[110]	_	_
12-24	1948-1951	the	abstract[105]|abstract[110]	giv[105]|giv[110]	_	_
12-25	1952-1963	composition	abstract[105]|abstract[110]	giv[105]|giv[110]	_	_
12-26	1964-1968	that	abstract[105]|abstract[110]	giv[105]|giv[110]	_	_
12-27	1969-1976	matters	abstract[105]|abstract[110]	giv[105]|giv[110]	_	_
12-28	1977-1978	.	_	_	_	_

#Text=For the same reasons , waist circumference is not the best method to assess obesity in these patients .
13-1	1979-1982	For	_	_	_	_
13-2	1983-1986	the	abstract[111]	new[111]	ana	14-4[117_111]
13-3	1987-1991	same	abstract[111]	new[111]	_	_
13-4	1992-1999	reasons	abstract[111]	new[111]	_	_
13-5	2000-2001	,	_	_	_	_
13-6	2002-2007	waist	object|place[113]	giv|giv[113]	_	_
13-7	2008-2021	circumference	place[113]	giv[113]	_	_
13-8	2022-2024	is	_	_	_	_
13-9	2025-2028	not	_	_	_	_
13-10	2029-2032	the	abstract[114]	new[114]	_	_
13-11	2033-2037	best	abstract[114]	new[114]	_	_
13-12	2038-2044	method	abstract[114]	new[114]	_	_
13-13	2045-2047	to	abstract[114]	new[114]	_	_
13-14	2048-2054	assess	abstract[114]	new[114]	_	_
13-15	2055-2062	obesity	abstract[114]|abstract	new[114]|giv	coref	16-9
13-16	2063-2065	in	abstract[114]	new[114]	_	_
13-17	2066-2071	these	abstract[114]|person[116]	new[114]|giv[116]	coref	14-22[124_116]
13-18	2072-2080	patients	abstract[114]|person[116]	new[114]|giv[116]	_	_
13-19	2081-2082	.	_	_	_	_

#Text=Trying to circumvent some of these limitations , the European Association for the Study of the Liver guidelines for nutrition in patients with cirrhosis recommend to adjust the BMI for the confounding effect of fluid retention ( i.e. , dry-BMI ) , though there is no perfect correlation between BMI and ascites , and in fact , BMI corrected for ascites drained at the time of LT failed to predict relevant outcomes after LT .
14-1	2083-2089	Trying	_	_	_	_
14-2	2090-2092	to	_	_	_	_
14-3	2093-2103	circumvent	_	_	_	_
14-4	2104-2108	some	abstract[117]	giv[117]	_	_
14-5	2109-2111	of	abstract[117]	giv[117]	_	_
14-6	2112-2117	these	abstract[117]|abstract[118]	giv[117]|giv[118]	_	_
14-7	2118-2129	limitations	abstract[117]|abstract[118]	giv[117]|giv[118]	_	_
14-8	2130-2131	,	_	_	_	_
14-9	2132-2135	the	organization[119]	new[119]	coref	18-18[176_119]
14-10	2136-2144	European	organization[119]	new[119]	_	_
14-11	2145-2156	Association	organization[119]	new[119]	_	_
14-12	2157-2160	for	organization[119]	new[119]	_	_
14-13	2161-2164	the	organization[119]|abstract[120]	new[119]|giv[120]	coref	18-22[177_120]
14-14	2165-2170	Study	organization[119]|abstract[120]	new[119]|giv[120]	_	_
14-15	2171-2173	of	organization[119]	new[119]	_	_
14-16	2174-2177	the	organization[119]|abstract[122]	new[119]|new[122]	_	_
14-17	2178-2183	Liver	organization[119]|object|abstract[122]	new[119]|giv|new[122]	coref	18-25[178_0]
14-18	2184-2194	guidelines	organization[119]|abstract[122]	new[119]|new[122]	_	_
14-19	2195-2198	for	organization[119]|abstract[122]	new[119]|new[122]	_	_
14-20	2199-2208	nutrition	organization[119]|abstract[122]|abstract	new[119]|new[122]|new	_	_
14-21	2209-2211	in	organization[119]|abstract[122]	new[119]|new[122]	_	_
14-22	2212-2220	patients	organization[119]|abstract[122]|person[124]	new[119]|new[122]|giv[124]	coref	17-3[168_124]
14-23	2221-2225	with	organization[119]|abstract[122]|person[124]	new[119]|new[122]|giv[124]	_	_
14-24	2226-2235	cirrhosis	organization[119]|abstract[122]|person[124]|substance	new[119]|new[122]|giv[124]|giv	_	_
14-25	2236-2245	recommend	_	_	_	_
14-26	2246-2248	to	_	_	_	_
14-27	2249-2255	adjust	_	_	_	_
14-28	2256-2259	the	organization[126]	giv[126]	coref	14-50[0_126]
14-29	2260-2263	BMI	organization[126]	giv[126]	_	_
14-30	2264-2267	for	_	_	_	_
14-31	2268-2271	the	abstract[127]	new[127]	appos	14-38[130_127]
14-32	2272-2283	confounding	abstract[127]	new[127]	_	_
14-33	2284-2290	effect	abstract[127]	new[127]	_	_
14-34	2291-2293	of	abstract[127]	new[127]	_	_
14-35	2294-2299	fluid	abstract[127]|substance|abstract[129]	new[127]|giv|new[129]	_	_
14-36	2300-2309	retention	abstract[127]|abstract[129]	new[127]|new[129]	_	_
14-37	2310-2311	(	_	_	_	_
14-38	2312-2316	i.e.	abstract[130]	giv[130]	_	_
14-39	2317-2318	,	abstract[130]	giv[130]	_	_
14-40	2319-2326	dry-BMI	abstract[130]	giv[130]	_	_
14-41	2327-2328	)	_	_	_	_
14-42	2329-2330	,	_	_	_	_
14-43	2331-2337	though	_	_	_	_
14-44	2338-2343	there	_	_	_	_
14-45	2344-2346	is	_	_	_	_
14-46	2347-2349	no	abstract[131]	new[131]	_	_
14-47	2350-2357	perfect	abstract[131]	new[131]	_	_
14-48	2358-2369	correlation	abstract[131]	new[131]	_	_
14-49	2370-2377	between	abstract[131]	new[131]	_	_
14-50	2378-2381	BMI	abstract[131]|organization	new[131]|giv	coref	14-58[134_0]
14-51	2382-2385	and	abstract[131]	new[131]	_	_
14-52	2386-2393	ascites	abstract[131]|abstract	new[131]|giv	coref	14-61[135_0]
14-53	2394-2395	,	_	_	_	_
14-54	2396-2399	and	_	_	_	_
14-55	2400-2402	in	_	_	_	_
14-56	2403-2407	fact	_	_	_	_
14-57	2408-2409	,	_	_	_	_
14-58	2410-2413	BMI	organization[134]	giv[134]	coref	15-3[139_134]
14-59	2414-2423	corrected	organization[134]	giv[134]	_	_
14-60	2424-2427	for	organization[134]	giv[134]	_	_
14-61	2428-2435	ascites	organization[134]|abstract[135]	giv[134]|giv[135]	_	_
14-62	2436-2443	drained	organization[134]|abstract[135]	giv[134]|giv[135]	_	_
14-63	2444-2446	at	organization[134]|abstract[135]	giv[134]|giv[135]	_	_
14-64	2447-2450	the	organization[134]|abstract[135]	giv[134]|giv[135]	_	_
14-65	2451-2455	time	organization[134]|abstract[135]	giv[134]|giv[135]	_	_
14-66	2456-2458	of	organization[134]|abstract[135]	giv[134]|giv[135]	_	_
14-67	2459-2461	LT	organization[134]|abstract[135]|abstract	giv[134]|giv[135]|giv	coref	14-74
14-68	2462-2468	failed	_	_	_	_
14-69	2469-2471	to	_	_	_	_
14-70	2472-2479	predict	_	_	_	_
14-71	2480-2488	relevant	abstract[137]	giv[137]	coref	15-34[149_137]
14-72	2489-2497	outcomes	abstract[137]	giv[137]	_	_
14-73	2498-2503	after	_	_	_	_
14-74	2504-2506	LT	abstract	giv	coref	16-35
14-75	2507-2508	.	_	_	_	_

#Text=Likewise , a modified BMI calculated by multiplying BMI ( kg/m2 ) by serum albumin ( g/L ) with the intention of compensating for volume overload was found of no use to predict clinical outcomes .
15-1	2509-2517	Likewise	_	_	_	_
15-2	2518-2519	,	_	_	_	_
15-3	2520-2521	a	organization[139]	giv[139]	coref	15-9[0_139]
15-4	2522-2530	modified	organization[139]	giv[139]	_	_
15-5	2531-2534	BMI	organization[139]	giv[139]	_	_
15-6	2535-2545	calculated	organization[139]	giv[139]	_	_
15-7	2546-2548	by	organization[139]	giv[139]	_	_
15-8	2549-2560	multiplying	organization[139]	giv[139]	_	_
15-9	2561-2564	BMI	organization[139]|organization	giv[139]|giv	coref	21-10
15-10	2565-2566	(	organization[139]	giv[139]	_	_
15-11	2567-2572	kg/m2	organization[139]|abstract	giv[139]|giv	_	_
15-12	2573-2574	)	organization[139]	giv[139]	_	_
15-13	2575-2577	by	organization[139]	giv[139]	_	_
15-14	2578-2583	serum	organization[139]|substance|substance[143]	giv[139]|new|new[143]	_	_
15-15	2584-2591	albumin	organization[139]|substance[143]	giv[139]|new[143]	_	_
15-16	2592-2593	(	organization[139]	giv[139]	_	_
15-17	2594-2597	g/L	organization[139]|abstract	giv[139]|new	_	_
15-18	2598-2599	)	organization[139]	giv[139]	_	_
15-19	2600-2604	with	organization[139]	giv[139]	_	_
15-20	2605-2608	the	organization[139]|abstract[145]	giv[139]|new[145]	_	_
15-21	2609-2618	intention	organization[139]|abstract[145]	giv[139]|new[145]	_	_
15-22	2619-2621	of	organization[139]|abstract[145]	giv[139]|new[145]	_	_
15-23	2622-2634	compensating	organization[139]|abstract[145]	giv[139]|new[145]	_	_
15-24	2635-2638	for	organization[139]|abstract[145]	giv[139]|new[145]	_	_
15-25	2639-2645	volume	organization[139]|abstract[145]|abstract|abstract[147]	giv[139]|new[145]|new|new[147]	_	_
15-26	2646-2654	overload	organization[139]|abstract[145]|abstract[147]	giv[139]|new[145]|new[147]	_	_
15-27	2655-2658	was	_	_	_	_
15-28	2659-2664	found	_	_	_	_
15-29	2665-2667	of	_	_	_	_
15-30	2668-2670	no	event[148]	giv[148]	_	_
15-31	2671-2674	use	event[148]	giv[148]	_	_
15-32	2675-2677	to	event[148]	giv[148]	_	_
15-33	2678-2685	predict	event[148]	giv[148]	_	_
15-34	2686-2694	clinical	event[148]|abstract[149]	giv[148]|giv[149]	coref	19-10[182_149]
15-35	2695-2703	outcomes	event[148]|abstract[149]	giv[148]|giv[149]	_	_
15-36	2704-2705	.	_	_	_	_

#Text=In conclusion , when available , we suggest obesity be defined according to the visceral fat area on body composition analysis , especially in the research setting , because the impact of obesity on LT may be modified by the coexistence of sarcopenia , myosteatosis , and/or low subcutaneous adipose tissue .
16-1	2706-2708	In	_	_	_	_
16-2	2709-2719	conclusion	_	_	_	_
16-3	2720-2721	,	_	_	_	_
16-4	2722-2726	when	_	_	_	_
16-5	2727-2736	available	_	_	_	_
16-6	2737-2738	,	_	_	_	_
16-7	2739-2741	we	person	acc	_	_
16-8	2742-2749	suggest	_	_	_	_
16-9	2750-2757	obesity	abstract	giv	coref	16-33
16-10	2758-2760	be	_	_	_	_
16-11	2761-2768	defined	_	_	_	_
16-12	2769-2778	according	_	_	_	_
16-13	2779-2781	to	_	_	_	_
16-14	2782-2785	the	abstract[152]	giv[152]	_	_
16-15	2786-2794	visceral	abstract[152]	giv[152]	_	_
16-16	2795-2798	fat	abstract[152]	giv[152]	_	_
16-17	2799-2803	area	abstract[152]	giv[152]	_	_
16-18	2804-2806	on	abstract[152]	giv[152]	_	_
16-19	2807-2811	body	abstract[152]|object|abstract[154]|abstract[155]	giv[152]|giv|giv[154]|new[155]	_	_
16-20	2812-2823	composition	abstract[152]|abstract[154]|abstract[155]	giv[152]|giv[154]|new[155]	_	_
16-21	2824-2832	analysis	abstract[152]|abstract[155]	giv[152]|new[155]	_	_
16-22	2833-2834	,	_	_	_	_
16-23	2835-2845	especially	abstract[157]	new[157]	_	_
16-24	2846-2848	in	abstract[157]	new[157]	_	_
16-25	2849-2852	the	abstract[157]	new[157]	_	_
16-26	2853-2861	research	abstract|abstract[157]	new|new[157]	_	_
16-27	2862-2869	setting	abstract[157]	new[157]	_	_
16-28	2870-2871	,	_	_	_	_
16-29	2872-2879	because	_	_	_	_
16-30	2880-2883	the	abstract[158]	new[158]	_	_
16-31	2884-2890	impact	abstract[158]	new[158]	_	_
16-32	2891-2893	of	abstract[158]	new[158]	_	_
16-33	2894-2901	obesity	abstract[158]|abstract	new[158]|giv	coref	18-5[172_0]
16-34	2902-2904	on	abstract[158]	new[158]	_	_
16-35	2905-2907	LT	abstract[158]|abstract	new[158]|giv	coref	17-9
16-36	2908-2911	may	_	_	_	_
16-37	2912-2914	be	_	_	_	_
16-38	2915-2923	modified	_	_	_	_
16-39	2924-2926	by	_	_	_	_
16-40	2927-2930	the	abstract[161]	new[161]	_	_
16-41	2931-2942	coexistence	abstract[161]	new[161]	_	_
16-42	2943-2945	of	abstract[161]	new[161]	_	_
16-43	2946-2956	sarcopenia	abstract[161]|abstract|abstract[163]	new[161]|giv|giv[163]	_	_
16-44	2957-2958	,	abstract[161]|abstract[163]	new[161]|giv[163]	_	_
16-45	2959-2971	myosteatosis	abstract[161]|abstract[163]|abstract	new[161]|giv[163]|giv	_	_
16-46	2972-2973	,	abstract[161]|abstract[163]	new[161]|giv[163]	_	_
16-47	2974-2980	and/or	abstract[161]|abstract[163]	new[161]|giv[163]	_	_
16-48	2981-2984	low	abstract[161]|abstract[163]|object[166]	new[161]|giv[163]|giv[166]	_	_
16-49	2985-2997	subcutaneous	abstract[161]|abstract[163]|object[166]	new[161]|giv[163]|giv[166]	_	_
16-50	2998-3005	adipose	abstract[161]|abstract[163]|abstract|object[166]	new[161]|giv[163]|giv|giv[166]	_	_
16-51	3006-3012	tissue	abstract[161]|abstract[163]|object[166]	new[161]|giv[163]|giv[166]	_	_
16-52	3013-3014	.	_	_	_	_

#Text=2.2. Should Morbidly Obese Patients be Listed for LT ?
17-1	3015-3019	2.2.	_	_	_	_
17-2	3020-3026	Should	_	_	_	_
17-3	3027-3035	Morbidly	abstract|person[168]	new|giv[168]	coref	20-4[184_168]
17-4	3036-3041	Obese	person[168]	giv[168]	_	_
17-5	3042-3050	Patients	person[168]	giv[168]	_	_
17-6	3051-3053	be	_	_	_	_
17-7	3054-3060	Listed	_	_	_	_
17-8	3061-3064	for	_	_	_	_
17-9	3065-3067	LT	abstract	giv	coref	18-2
17-10	3068-3069	?	_	_	_	_

#Text=Some LT programs consider morbid obesity a relative contraindication for LT based on the latest recommendations from the American Association for the Study of the Liver .
18-1	3070-3074	Some	organization[171]	new[171]	_	_
18-2	3075-3077	LT	abstract|organization[171]	giv|new[171]	coref	18-11
18-3	3078-3086	programs	organization[171]	new[171]	_	_
18-4	3087-3095	consider	_	_	_	_
18-5	3096-3102	morbid	abstract[172]	giv[172]	coref	19-8[0_172]
18-6	3103-3110	obesity	abstract[172]	giv[172]	_	_
18-7	3111-3112	a	abstract[173]	new[173]	coref	23-37[228_173]
18-8	3113-3121	relative	abstract[173]	new[173]	_	_
18-9	3122-3138	contraindication	abstract[173]	new[173]	_	_
18-10	3139-3142	for	abstract[173]	new[173]	_	_
18-11	3143-3145	LT	abstract[173]|abstract	new[173]|giv	coref	19-12
18-12	3146-3151	based	_	_	_	_
18-13	3152-3154	on	_	_	_	_
18-14	3155-3158	the	abstract[175]	new[175]	_	_
18-15	3159-3165	latest	abstract[175]	new[175]	_	_
18-16	3166-3181	recommendations	abstract[175]	new[175]	_	_
18-17	3182-3186	from	abstract[175]	new[175]	_	_
18-18	3187-3190	the	abstract[175]|organization[176]	new[175]|giv[176]	_	_
18-19	3191-3199	American	abstract[175]|organization[176]	new[175]|giv[176]	_	_
18-20	3200-3211	Association	abstract[175]|organization[176]	new[175]|giv[176]	_	_
18-21	3212-3215	for	abstract[175]|organization[176]	new[175]|giv[176]	_	_
18-22	3216-3219	the	abstract[175]|organization[176]|abstract[177]	new[175]|giv[176]|giv[177]	_	_
18-23	3220-3225	Study	abstract[175]|organization[176]|abstract[177]	new[175]|giv[176]|giv[177]	_	_
18-24	3226-3228	of	abstract[175]|organization[176]|abstract[177]	new[175]|giv[176]|giv[177]	_	_
18-25	3229-3232	the	abstract[175]|organization[176]|abstract[177]|object[178]	new[175]|giv[176]|giv[177]|giv[178]	coref	22-26[0_178]
18-26	3233-3238	Liver	abstract[175]|organization[176]|abstract[177]|object[178]	new[175]|giv[176]|giv[177]|giv[178]	_	_
18-27	3239-3240	.	_	_	_	_

#Text=However , evidence evaluating the role of obesity on outcomes after LT is conflicting .
19-1	3241-3248	However	_	_	_	_
19-2	3249-3250	,	_	_	_	_
19-3	3251-3259	evidence	abstract[179]	new[179]	coref	21-1[0_179]
19-4	3260-3270	evaluating	abstract[179]	new[179]	_	_
19-5	3271-3274	the	abstract[179]|abstract[180]	new[179]|new[180]	_	_
19-6	3275-3279	role	abstract[179]|abstract[180]	new[179]|new[180]	_	_
19-7	3280-3282	of	abstract[179]|abstract[180]	new[179]|new[180]	_	_
19-8	3283-3290	obesity	abstract[179]|abstract[180]|abstract	new[179]|new[180]|giv	coref	20-6[185_0]
19-9	3291-3293	on	abstract[179]|abstract[180]	new[179]|new[180]	_	_
19-10	3294-3302	outcomes	abstract[179]|abstract[180]|abstract[182]	new[179]|new[180]|giv[182]	coref	22-17[211_182]
19-11	3303-3308	after	abstract[179]|abstract[180]|abstract[182]	new[179]|new[180]|giv[182]	_	_
19-12	3309-3311	LT	abstract[179]|abstract[180]|abstract[182]|abstract	new[179]|new[180]|giv[182]|giv	coref	20-13
19-13	3312-3314	is	_	_	_	_
19-14	3315-3326	conflicting	_	_	_	_
19-15	3327-3328	.	_	_	_	_

#Text=When needed , patients with severe and morbid obesity do benefit from LT , meaning they live longer than they would do without it , and LT in these patients strays far away from being futile , with five-year survival rates well above 50 % .
20-1	3329-3333	When	_	_	_	_
20-2	3334-3340	needed	_	_	_	_
20-3	3341-3342	,	_	_	_	_
20-4	3343-3351	patients	person[184]	giv[184]	ana	20-16[0_184]
20-5	3352-3356	with	person[184]	giv[184]	_	_
20-6	3357-3363	severe	person[184]|abstract[185]	giv[184]|giv[185]	coref	21-20[0_185]
20-7	3364-3367	and	person[184]|abstract[185]	giv[184]|giv[185]	_	_
20-8	3368-3374	morbid	person[184]|abstract[185]	giv[184]|giv[185]	_	_
20-9	3375-3382	obesity	person[184]|abstract[185]	giv[184]|giv[185]	_	_
20-10	3383-3385	do	_	_	_	_
20-11	3386-3393	benefit	_	_	_	_
20-12	3394-3398	from	_	_	_	_
20-13	3399-3401	LT	abstract	giv	ana	20-24
20-14	3402-3403	,	_	_	_	_
20-15	3404-3411	meaning	_	_	_	_
20-16	3412-3416	they	person	giv	ana	20-20
20-17	3417-3421	live	_	_	_	_
20-18	3422-3428	longer	_	_	_	_
20-19	3429-3433	than	_	_	_	_
20-20	3434-3438	they	person	giv	coref	20-29[191_0]
20-21	3439-3444	would	_	_	_	_
20-22	3445-3447	do	_	_	_	_
20-23	3448-3455	without	_	_	_	_
20-24	3456-3458	it	abstract	giv	coref	20-27[190_0]
20-25	3459-3460	,	_	_	_	_
20-26	3461-3464	and	_	_	_	_
20-27	3465-3467	LT	abstract[190]	giv[190]	coref	21-17[0_190]
20-28	3468-3470	in	abstract[190]	giv[190]	_	_
20-29	3471-3476	these	abstract[190]|person[191]	giv[190]|giv[191]	_	_
20-30	3477-3485	patients	abstract[190]|person[191]	giv[190]|giv[191]	_	_
20-31	3486-3492	strays	_	_	_	_
20-32	3493-3496	far	_	_	_	_
20-33	3497-3501	away	_	_	_	_
20-34	3502-3506	from	_	_	_	_
20-35	3507-3512	being	_	_	_	_
20-36	3513-3519	futile	_	_	_	_
20-37	3520-3521	,	_	_	_	_
20-38	3522-3526	with	_	_	_	_
20-39	3527-3536	five-year	abstract[193]	new[193]	_	_
20-40	3537-3545	survival	event|abstract[193]	new|new[193]	coref	22-33[216_0]
20-41	3546-3551	rates	abstract[193]	new[193]	_	_
20-42	3552-3556	well	_	_	_	_
20-43	3557-3562	above	_	_	_	_
20-44	3563-3565	50	_	_	_	_
20-45	3566-3567	%	_	_	_	_
20-46	3568-3569	.	_	_	_	_

#Text=Evidence so far does not support using a strict BMI cutoff to deny someone candidacy for LT , however obesity is frequently associated with other conditions that may be contraindications for LT such as cardiovascular disease , cancer , renal dysfunction , and pulmonary hypertension .
21-1	3570-3578	Evidence	abstract	giv	_	_
21-2	3579-3581	so	_	_	_	_
21-3	3582-3585	far	_	_	_	_
21-4	3586-3590	does	_	_	_	_
21-5	3591-3594	not	_	_	_	_
21-6	3595-3602	support	_	_	_	_
21-7	3603-3608	using	_	_	_	_
21-8	3609-3610	a	abstract[196]	new[196]	_	_
21-9	3611-3617	strict	abstract[196]	new[196]	_	_
21-10	3618-3621	BMI	organization|abstract[196]	giv|new[196]	_	_
21-11	3622-3628	cutoff	abstract[196]	new[196]	_	_
21-12	3629-3631	to	_	_	_	_
21-13	3632-3636	deny	_	_	_	_
21-14	3637-3644	someone	person	new	_	_
21-15	3645-3654	candidacy	_	_	_	_
21-16	3655-3658	for	_	_	_	_
21-17	3659-3661	LT	abstract	giv	coref	21-32
21-18	3662-3663	,	_	_	_	_
21-19	3664-3671	however	_	_	_	_
21-20	3672-3679	obesity	abstract	giv	coref	22-3
21-21	3680-3682	is	_	_	_	_
21-22	3683-3693	frequently	_	_	_	_
21-23	3694-3704	associated	_	_	_	_
21-24	3705-3709	with	_	_	_	_
21-25	3710-3715	other	abstract[200]	new[200]	_	_
21-26	3716-3726	conditions	abstract[200]	new[200]	_	_
21-27	3727-3731	that	abstract[200]|abstract[201]	new[200]|new[201]	_	_
21-28	3732-3735	may	abstract[200]|abstract[201]	new[200]|new[201]	_	_
21-29	3736-3738	be	abstract[200]|abstract[201]	new[200]|new[201]	_	_
21-30	3739-3756	contraindications	abstract[200]|abstract[201]	new[200]|new[201]	_	_
21-31	3757-3760	for	abstract[200]|abstract[201]	new[200]|new[201]	_	_
21-32	3761-3763	LT	abstract[200]|abstract[201]|abstract	new[200]|new[201]|giv	coref	23-22
21-33	3764-3768	such	abstract[200]	new[200]	_	_
21-34	3769-3771	as	abstract[200]	new[200]	_	_
21-35	3772-3786	cardiovascular	abstract[200]|abstract[203]	new[200]|new[203]	coref	22-26[215_203]
21-36	3787-3794	disease	abstract[200]|abstract[203]	new[200]|new[203]	_	_
21-37	3795-3796	,	abstract[200]	new[200]	_	_
21-38	3797-3803	cancer	abstract[200]|abstract	new[200]|new	_	_
21-39	3804-3805	,	abstract[200]	new[200]	_	_
21-40	3806-3811	renal	abstract[200]|abstract[205]	new[200]|new[205]	_	_
21-41	3812-3823	dysfunction	abstract[200]|abstract[205]	new[200]|new[205]	_	_
21-42	3824-3825	,	abstract[200]	new[200]	_	_
21-43	3826-3829	and	abstract[200]	new[200]	_	_
21-44	3830-3839	pulmonary	abstract[200]|abstract[206]	new[200]|new[206]	_	_
21-45	3840-3852	hypertension	abstract[200]|abstract[206]	new[200]|new[206]	_	_
21-46	3853-3854	.	_	_	_	_

#Text=Also , obesity is a risk factor for NAFLD , which though traditionally considered to have similar post-LT outcomes to those of other etiologies of liver disease , may in fact have lower one-year survival due to cardiovascular and cerebrovascular diseases .
22-1	3855-3859	Also	_	_	_	_
22-2	3860-3861	,	_	_	_	_
22-3	3862-3869	obesity	abstract	giv	coref	22-5[209_0]
22-4	3870-3872	is	_	_	_	_
22-5	3873-3874	a	abstract[209]	giv[209]	coref	23-6[218_209]
22-6	3875-3879	risk	abstract|abstract[209]	new|giv[209]	_	_
22-7	3880-3886	factor	abstract[209]	giv[209]	_	_
22-8	3887-3890	for	abstract[209]	giv[209]	_	_
22-9	3891-3896	NAFLD	abstract[209]|abstract[210]	giv[209]|new[210]	ana	22-21[212_210]
22-10	3897-3898	,	abstract[209]|abstract[210]	giv[209]|new[210]	_	_
22-11	3899-3904	which	abstract[209]|abstract[210]	giv[209]|new[210]	_	_
22-12	3905-3911	though	abstract[209]|abstract[210]	giv[209]|new[210]	_	_
22-13	3912-3925	traditionally	abstract[209]|abstract[210]	giv[209]|new[210]	_	_
22-14	3926-3936	considered	abstract[209]|abstract[210]	giv[209]|new[210]	_	_
22-15	3937-3939	to	abstract[209]|abstract[210]	giv[209]|new[210]	_	_
22-16	3940-3944	have	abstract[209]|abstract[210]	giv[209]|new[210]	_	_
22-17	3945-3952	similar	abstract[209]|abstract[210]|abstract[211]	giv[209]|new[210]|giv[211]	coref	23-22[225_211]
22-18	3953-3960	post-LT	abstract[209]|abstract[210]|abstract[211]	giv[209]|new[210]|giv[211]	_	_
22-19	3961-3969	outcomes	abstract[209]|abstract[210]|abstract[211]	giv[209]|new[210]|giv[211]	_	_
22-20	3970-3972	to	_	_	_	_
22-21	3973-3978	those	abstract[212]	giv[212]	_	_
22-22	3979-3981	of	abstract[212]	giv[212]	_	_
22-23	3982-3987	other	abstract[212]|abstract[213]	giv[212]|new[213]	_	_
22-24	3988-3998	etiologies	abstract[212]|abstract[213]	giv[212]|new[213]	_	_
22-25	3999-4001	of	abstract[212]|abstract[213]	giv[212]|new[213]	_	_
22-26	4002-4007	liver	abstract[212]|abstract[213]|object|abstract[215]	giv[212]|new[213]|giv|giv[215]	_	_
22-27	4008-4015	disease	abstract[212]|abstract[213]|abstract[215]	giv[212]|new[213]|giv[215]	_	_
22-28	4016-4017	,	_	_	_	_
22-29	4018-4021	may	_	_	_	_
22-30	4022-4024	in	_	_	_	_
22-31	4025-4029	fact	_	_	_	_
22-32	4030-4034	have	_	_	_	_
22-33	4035-4040	lower	event[216]	giv[216]	_	_
22-34	4041-4049	one-year	event[216]	giv[216]	_	_
22-35	4050-4058	survival	event[216]	giv[216]	_	_
22-36	4059-4062	due	_	_	_	_
22-37	4063-4065	to	_	_	_	_
22-38	4066-4080	cardiovascular	abstract[217]	new[217]	_	_
22-39	4081-4084	and	abstract[217]	new[217]	_	_
22-40	4085-4100	cerebrovascular	abstract[217]	new[217]	_	_
22-41	4101-4109	diseases	abstract[217]	new[217]	_	_
22-42	4110-4111	.	_	_	_	_

#Text=In summary , more than obesity itself , it is the sum of the comorbidities of the individual patient that determines LT outcomes and as such , morbid obesity should not be considered on its own a contraindication for LT , but in turn should trigger a rigorous pre-LT assessment to carefully select potential recipients , as discussed below .
23-1	4112-4114	In	_	_	_	_
23-2	4115-4122	summary	_	_	_	_
23-3	4123-4124	,	_	_	_	_
23-4	4125-4129	more	_	_	_	_
23-5	4130-4134	than	_	_	_	_
23-6	4135-4142	obesity	abstract[218]	giv[218]	ana	23-7[0_218]
23-7	4143-4149	itself	abstract[218]|abstract	giv[218]|giv	ana	23-9
23-8	4150-4151	,	_	_	_	_
23-9	4152-4154	it	abstract	giv	coref	23-11[221_0]
23-10	4155-4157	is	_	_	_	_
23-11	4158-4161	the	abstract[221]	giv[221]	coref	23-28[226_221]
23-12	4162-4165	sum	abstract[221]	giv[221]	_	_
23-13	4166-4168	of	abstract[221]	giv[221]	_	_
23-14	4169-4172	the	abstract[221]|abstract[222]	giv[221]|new[222]	_	_
23-15	4173-4186	comorbidities	abstract[221]|abstract[222]	giv[221]|new[222]	_	_
23-16	4187-4189	of	abstract[221]|abstract[222]	giv[221]|new[222]	_	_
23-17	4190-4193	the	abstract[221]|abstract[222]|person[223]	giv[221]|new[222]|giv[223]	_	_
23-18	4194-4204	individual	abstract[221]|abstract[222]|person[223]	giv[221]|new[222]|giv[223]	_	_
23-19	4205-4212	patient	abstract[221]|abstract[222]|person[223]	giv[221]|new[222]|giv[223]	_	_
23-20	4213-4217	that	abstract[221]	giv[221]	_	_
23-21	4218-4228	determines	abstract[221]	giv[221]	_	_
23-22	4229-4231	LT	abstract[221]|abstract|abstract[225]	giv[221]|giv|giv[225]	coref	23-40
23-23	4232-4240	outcomes	abstract[221]|abstract[225]	giv[221]|giv[225]	_	_
23-24	4241-4244	and	_	_	_	_
23-25	4245-4247	as	_	_	_	_
23-26	4248-4252	such	_	_	_	_
23-27	4253-4254	,	_	_	_	_
23-28	4255-4261	morbid	abstract[226]	giv[226]	ana	23-35[0_226]
23-29	4262-4269	obesity	abstract[226]	giv[226]	_	_
23-30	4270-4276	should	_	_	_	_
23-31	4277-4280	not	_	_	_	_
23-32	4281-4283	be	_	_	_	_
23-33	4284-4294	considered	_	_	_	_
23-34	4295-4297	on	_	_	_	_
23-35	4298-4301	its	abstract	giv	_	_
23-36	4302-4305	own	_	_	_	_
23-37	4306-4307	a	abstract[228]	giv[228]	_	_
23-38	4308-4324	contraindication	abstract[228]	giv[228]	_	_
23-39	4325-4328	for	abstract[228]	giv[228]	_	_
23-40	4329-4331	LT	abstract[228]|abstract	giv[228]|giv	_	_
23-41	4332-4333	,	_	_	_	_
23-42	4334-4337	but	_	_	_	_
23-43	4338-4340	in	_	_	_	_
23-44	4341-4345	turn	_	_	_	_
23-45	4346-4352	should	_	_	_	_
23-46	4353-4360	trigger	_	_	_	_
23-47	4361-4362	a	abstract[230]	new[230]	_	_
23-48	4363-4371	rigorous	abstract[230]	new[230]	_	_
23-49	4372-4378	pre-LT	abstract[230]	new[230]	_	_
23-50	4379-4389	assessment	abstract[230]	new[230]	_	_
23-51	4390-4392	to	_	_	_	_
23-52	4393-4402	carefully	_	_	_	_
23-53	4403-4409	select	_	_	_	_
23-54	4410-4419	potential	person[231]	new[231]	_	_
23-55	4420-4430	recipients	person[231]	new[231]	_	_
23-56	4431-4432	,	_	_	_	_
23-57	4433-4435	as	_	_	_	_
23-58	4436-4445	discussed	_	_	_	_
23-59	4446-4451	below	_	_	_	_
23-60	4452-4453	.	_	_	_	_
